AAH Pharmaceuticals is investing around £30m to upgrade its 900+ fleet of temperature-controlled vans, bringing significant improvements in reliability and efficiency that will also benefit customers.
Work on the three-year programme is already underway with December’s arrival of 328 new pharma vans, valued at £11.2m. These feature a more efficient cooling system for the control of ambient temperatures, replacing the internal air conditioning system seen on previous models. The technology guarantees the temperatures needed to safely deliver medicines and other stock items to pharmacies, hospitals and dispensing doctors nationwide.
The business has also introduced an improved and much more agile telematics solution, helping it to plan and organise more efficient delivery routes. This will cut both fuel costs and emissions.
The new Euro 6 vehicles will further help to reduce the company’s carbon footprint, eliminating up to 19,550 tonnes of carbon emissions per week. This equates to over one million tonnes of CO2 per year and supports the firm’s commitment to be carbon-neutral by 2030.
Toby Anderson, CEO of parent firm McKesson UK, said: “The roll-out of a brand-new pharmavan fleet marks a significant investment in the company, to make our operations more efficient, to deliver a better service, and to support our sustainability pledge. Our new vans will continue to be industry-leading in the final-mile delivery of pharmaceuticals to our customers, helping us deliver products to our customers in the most compliant, efficient way.”
